EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

SLD Summit 2025

 

23-25 January, Estoril
Close
N. Poster
Poster title
Applicant name
Status
  1-PO7 Efficacy of essential phospholipids in reducing hepatic steatosis in patients with different stages of metabolic dysfunction-associated steatotic liver disease A phase IV study Norbert Stefan Received Received
  1-PO3 Association between sarcopenia and coronary atherosclerosis in metabolic dysfunction-associated steatotic liver disease Yeonjung Ha Received Received
  1-PO6 Muscle composition predicts adverse outcomes in chronic liver disease: A 5-year follow-up study Wile Balkhed Received Received
  1-PO4 The impact of cardiopulmonary fitness on MASLD in a combined lifestyle intervention for adolescents with obesity Maarten Buytaert Received Received
  1-PO2 Microvascular complications of type 2 diabetes mellitus in patients with concomitant metabolic dysfunction-associated steatotic liver disease in primary care, a prospective cohort study Martin Bergram Received Received
  1-PO1 Comparison of transient elastography and shear wave elastography in patients with MAFLD: A single-center experience Ahmed El Fayoumi Received Received
  1-PO5 PDE4 inhibition mitigates metabolic-associated steatotic liver disease by reducing lipogenesis and enhancing triglyceride secretion in obese mice da Silva Hellen Received Received
  2-PO4 Distinct roles of hepatic S100A10 and S100A11 in metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma Etienne Delangre Received Received
  2-PO3 Evaluation of long-term changes in liver function and structure in patients exposed to SARS-CoV-2 infection: a prospective study Erkin Saeed Saifi Received Received
  2-PO1 Fibrinolytic activity of blood plasma in pregnant women with MASH against various degrees of obesity Lina Bahniy Received Received
  2-PO5 Morphological changes in liver cirrhosis on imaging and associations to clinical parameters, liver stiffness, steatosis and etiology signe swerkersson Received Received
  2-PO6 Insulin resistance and sarcopenia in patients with MASLD: Is there a relationship? Kateryna Pivtorak Received Received
  2-PO2 Relationship between endothelial dysfunction and metabolic dysfunction-associated steatotic liver disease Kateryna Pivtorak Received Received
  3-PO3 The mechanisms of metabolic dysfunction-associated steatotic liver disease(MASLD) development: what can we learn from a MASLD-resistant porcine model? Miranda Dosi Received Received
  3-PO4 The effect of obesity and hepatic steatosis on the course and outcomes of COVID 19-associated pneumonia in patients with metabolic dysfunction-associated steatotic liver disease Taisiia Turankova Received Received
  3-PO7 Association of cardiometabolic risk and phenotypic age with the course of metabolic dysfunction-associated steatotic liver disease Anastasiia Radchenko Received Received
  3-PO5 Exposure to the environmental Bisphenol A influences trained immunity-related pathways in metabolic dysfunction-associated steatotic liver disease (MASLD): A preliminary observation Marcello Dallio Received Received
  3-PO1 The dietitians role in the pre-operative workup for patients undergoing laparoscopic surgery of the upper GIT Mico Price Received Received
  3-PO6 Rural-urban differentials in health literacy of metabolic dysfunction-associated steatotic liver disease Varathpavee Bhuriveth Received Received
  3-PO2 Digital communication intervention and weight loss in patients with metabolic dysfunction-associated steatotic liver disease: A randomised controlled Study Sakkarin Chirapongsathorn Received Received
  4-PO6 Modest alcohol consumption influences on the spectrum of bile acids in individuals with intact liver function, resembling the changes in patients with MASLD Olena Barabanchyk Received Received
  4-PO5 Prevalence and health literacy of metabolic dysfunction-associated steatotic liver disease and its associated factors in a rural area: a cross-sectional study Varathpavee Bhuriveth Received Received
  4-PO3 From MAFLD to MASLD: a real-life head-to-head comparison of MAFLD and MASLD criteria in estimating liver disease progression risk in not-lean and lean subjects Fiammetta Di Nardo Received Received
  4-PO1 FLAME model: validation of a tool incorporating alpha-glutathione-s-transferase serum levels for predicting advanced fibrosis and cardiovascular events in MASLD Mario Romeo Received Received
  4-PO4 Prevalence of MASLD and its association with the consumption of sugar sweetened beverages among a non-communicable disease cohort in the rural district of Iringa, Tanzania VALENTIN CALVEZ Received Received
  4-PO7 Advanced fibrosis affects quality of life and muscle function in patients with metabolic-dysfunction associated steatotic liver disease Pinelopi Manousou Received Received
  4-PO2 MASLD and fibrosis status in patients with type 2 diabetes treated at internal medicine clinics: Türkiye DAHUDER awareness of steatotic liver disease (TR-DASLD) study yasin &351;ahintürk Received Received
  5-PO4 A prove-of-concept study of pioglitazone low dose vs standard dose for the treatment of metabolic dysfunction-associated steatohepatitis Sakkarin Chirapongsathorn Received Received
  5-PO3 Advanced unbiased proteomics reveals new molecular mechanisms in steatotic liver disease Elena Bonzón Kulichenko Received Received
  5-PO2 Differences in gut microbiome diversity in patients with metabolic dysfunction-associated steatotic liver disease associate with response to faecal microbiota transplant pinelopi manousou Received Received
  5-PO6 Predictive factors for hepatocellular carcinoma development in patients with metabolic-dysfunction-associated steatotic liver disease with or without cirrhosis Pinelopi Manousou Received Received
  5-PO1 Cholesterol exacerbates the pathophysiology of metabolic dysfunction-associated steatohepatitis by upregulating Hypoxia-Inducible Factor 1 and modulating microcirculatory dysfunction Evelyn Pereira Received Received
  5-PO7 Therapeutic potential and safety profiles of resmetirom in the treatment of non-alcoholic steatohepatitis: a systematic review and meta-analysis Varathpavee Bhuriveth Received Received
  5-PO5 The pan-PPAR agonist lanifibranor improves liver inflammation, ballooning, and fibrosis in a diet-induced obese MASH hamster model of binge drinking FRANCOIS BRIAND Received Received
  6-PO7 Enhancing trial recruitment in MetALD and ALD with LiverPRO to detect fibrosis Katrine Lindvig Received Received
  6-PO4 Multidisciplinary management combining hepatologist counseling, cognitive/behavioral therapy, and nutritional support (the CoCoNut protocol) improves the clinical outcomes of MASLD patients Marcello Dallio Received Received
  6-PO1 Normal fibrosis-4 values do not exclude advanced fibrosis in 15 of patients with metabolic dysfunction-associated steatotic liver disease Pinelopi Manousou Received Received
  6-PO6 Inter-observer variability of liver biopsy reading in clinical trials for metabolic dysfunction-associated steatohepatitis: A monocentric experience Sebastiano Archilei Received Received
  6-PO5 A targeted steroidomic approach to investigate the impact of sexual dimorphism on liver damage in patients with metabolic-dysfunction associated steatotic liver disease Eleonora Dileo Received Received
  6-PO3 The impact of diabetes mellitus and glucagon-like peptide-1 agonists on frailty for patients with advanced chronic liver disease Matthew McKenna-Barry Received Received
  7-PO2 Fibrosis stage versus fibrosis-4 score for predicting clinical outcomes in metabolic dysfunction-associated steatotic liver disease, and evaluation of healthcare resource utilization and associated costs Hannes Hagström Received Received
  7-PO4 Circulating EV-miRs for the diagnosis and staging of MASLD and hepatocellular carcinoma Santiago Iturbe-Rey Received Received
  7-PO7 Modeling metabolic-dysfunction associated steatotic liver disease in juvenile zebrafish: a novel platform for disease study and drug discovery Helena Sarret Casellas Received Received
  7-PO1 A randomized controlled study of daily aspirin to reduce fibrosis progression in metabolic dysfunction-associated steatotic liver disease Khanisorn Meesri Received Received
  7-PO5 Relationships between fibrosis status, multimorbidity, and all-cause mortality in people with metabolic-dysfunction associated steatotic liver disease in UK Biobank Qi Feng Received Received
  7-PO3 Immune landscaping in a mouse model unveils an immunosuppressive cell composition in hepatic crown-like structures involved in metabolic dysfunction-associated steatohepatitis Ainhoa Asensio Aldave Received Received
  7-PO6 Steatotic liver disease (SLD) in the adult population attending a health check-up program in Thailand: Prevalence and fibrosis status Pimsiri Sripongpun Received Received
  8-PO1 HK3, a novel MASH drug with profound anti-obesity action Juergen Eckel Received Received
  8-PO4 Effect of diabetes treatment and antilipidemic drugs on metabolic dysfunction-associated steatotic liver disease in type 2 diabetic patients Zülal &304;stemihan Received Received
  8-PO3 Liver adrenoceptor alpha-1b plays a protective role in MASLD progression Bernie Efole Received Received
  8-PO7 Impact of type 2 diabetes on hepatic fibrosis in patients with MASLD Paula Mesquita Received Received
  8-PO5 Statin, but not aspirin use is inversely associated with steatotic liver disease and increased liver stiffness: Results from two large prospective population based studies Jesse Pustjens Received Received
  8-PO2 Advanced metabolic-dysfunction associated steatotic liver disease fibrosis: Low number-needed-to screen in multiple lines of care A.G. (Onno) Holleboom Received Received
  8-PO6 MASLD and FIB4 are independent predictors of major adverse liver outcomes and cardiovascular events in type 2 diabetes: findings from a single-center cohort using AI-driven machine learning Valentin Calvez Received Received
  9-PO7 Higher cut off values of CAP is needed to avoid over diagnosis of steatosis in obese patients Gamal Shiha Received Received
  9-PO5 Prevalence of low ceruloplasmin in patients with alcohol use disorder Hanna Blaney Received Received
  9-PO6 Distinct postprandial metabolic and inflammatory responses in healthy individuals versus patients with metabolic dysfunction-associated steatotic liver disease Sinéad Mullin Received Received
  9-PO1 The vitamin E conundrum: Should you still be using it for metabolic dysfunction-associated steatotic liver disease (MASLD) Shweh Fern Loo Received Received
  9-PO4 Degree of adherence to the mediterranean diet is highly predictive of prognosis in patients with MASLD: Findings from NHANES 2011-2018 Tsubasa Tsutsumi Received Received
  9-PO2 Association of newly-onset dyslipidemia and metabolic dysfunction-associated steatotic liver disease (MASLD) among chronic hepatitis B patients with antivirus treatment in China Sijia Dong Received Received
  9-PO3 Validation of PNPLA3 polymorphisms as risk factor for MASLD and MASH in Southeast Asian populations with MASLD Sakkarin Chirapongsathorn Received Received
  10-PO4 Hepatoprotective effects of fatty acid synthase inhibitor TVB-3664 in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH Michael Feigh Received Received
  10-PO3 Determining the prevalence and characterizing the associated factors and health outcomes related to Metabolic dysfunction-associated steatotic liver disease (MASLD) and Metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes mellitus at Sultan Qaboos University Hospital: A prospective cohort study Dalal Al-Harthi Received Received
  10-PO7 Nationwide Comparison of the Epidemiology of MASLD and ALD in the Entire Korean Population from 2010 to 2022 Chang-Gue Son Received Received
  10-PO1 Clinical superior applicability and repeatability of Hepatoscope 2DTE thanks to imaging-related criteria Cindy Serdjebi Received Received
  10-PO2 A serial investigation to develop herbal-derived therapeutics targeting MASLD and metabolic syndrome using Amomum Xanthioides Seung-Ju Hwang Received Received
  10-PO6 Prevalence of steatosis and steatohepatitis in patients undergoing bariatric surgery: A biopsy-based study Gamal Shiha Received Received
  10-PO5 Hepatocyte-derived extracellular vesicles carrying miR-21 trigger muscle cell dysfunction Diogo Alexandre Fernandes Received Received
  11-PO2 Paving the way for MASH screening of high-risk patients in primary and secondary care Sofia Carvalhana Received Received
  11-PO3 Prevalence of multifactorial steatotic liver disease: Why it should be included in the international classification of steatotic liver disease ROSANNA VILLANI Received Received
  11-PO7 Risk-stratification of patients with metabolic dysfunction-associated steatotic liver disease and indeterminate vibration-controlled transient elastography David Marti-Aguado Received Received
  11-PO5 Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in four cities in the United States, including among people with diabetes and primary care providers Jeffrey V Lazarus Received Received
  11-PO6 ASAP score for HCC risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up Marta Guariglia Received Received
  11-PO4 High burden of MASLD and metALD in People with HIV: A call for liver fibrosis screening prioritization Felice Cinque Received Received
  12-PO2 Metabolic associated steatotic liver disease and mental illness: role of fibroblast growth factor-21 Karen Houseknecht Received Received
  12-PO3 The pattern of liver enzymes enhances the prognostic value of the Fibrosis-4 index for patients with metabolic dysfunctionassociated steatotic liver disease Emma Hajaj Received Received
  12-PO5 Unveiling the hidden link: Psoriasis and liver disease risk Silvia Zanella Received Received
  12-PO6 Association between polycystic ovary syndrome, steatotic liver disease in pregnancy, and adverse pregnancy outcomes: results from the prospective Fatty Liver in Pregnancy cohort Cecilia Katzenstein Received Received
  12-PO4 Exploring the interplay between sarcopenia, liver and cardiovascular damage in non-cirrhotic MASLD patients: a genetic perspective Annalisa Cespiati Received Received
  12-PO7 Use of Glucagon-like peptide-1 receptor agonist is associated with reduced risk of major liver-related events: A meta-analysis Ciro Celsa Received Received
  12-PO1 Hormetic effects of 7-Ketocholesterol in preventing ferroptosis-induced hepatocyte death Oren Tirosh Received Received
  13-PO2 Assessing the impact of glucagon-like peptide-1 receptor agonists in metabolic dysfunction associated steatosis liver disease Amreen Dinani Received Received
  13-PO1 Alcohol and metabolic factors influence steatotic liver disease clinical outcomes Katrina Pekarska Received Received
  13-PO3 JAK2 inhibitor ruxolitinib ameliorates portal hypertension associated with metabolic dysfunction-associated liver disease yingjie Ai Received Received
  13-PO7 Role of genetic variants in association with the severity of liver fibrosis and steatosis in patients with steatotic liver disease Pisit Tangkijvanich Received Received
  13-PO6 Diagnosis, prognosis and sequential use of non-invasive tests in patients with MetALD Nikolaj Torp Received Received
  13-PO4 Risk factor awareness for liver disease in four United States cities Jeffrey V Lazarus Received Received
  14-PO1 Diagnostic performance of serum mac-2-binding protein glycosylation isomer as a fibrosis biomarker in non-obese and obese patients with steatotic liver disease Pisit Tangkijvanich Received Received
  14-PO6 Fast and robust MRI assessment of abdominal obesity and liver tissue characteristics a population-scale analysis Magdalena Nowak Received Received
  14-PO5 10 year progression of metabolic risk factors - correlation with steatosis and fibrosis degree in a general population cohort Joana Estrabocha Received Received
  14-PO2 Effect of constitutive androstane receptor activation on hepatic unsaturated triglyceride levels Petr Pavek Received Received
  14-PO7 A comparison of the prognostic value of 10 body composition markers for steatosis, MASH and fibrosis in a general population setting Laurens van Kleef Received Received
  14-PO3 Arsenic as a risk factor for hepatocellular carcinoma (HCC) risk among patients with metabolic associated liver disease (MASLD) Priya Roy Received Received
  15-PO2 Arsenic as a risk factor for metabolic-associated steatotic liver disease (MASLD): A mechanistic study Priya Roy Received Received
  15-PO3 Low doses of bacterial D-lactate modulate liver steatosis and ameliorate experimental MASLD André Santos Received Received
  15-PO5 Does cardiovascular risk differ with age-specific body composition in women with in metabolic dysfunction-associated steatotic liver disease? Mariana Ramírez-Mejía Received Received
  15-PO1 Anti-steatotic capacity screen for metabolic-associated steatotic liver disease therapeutics Victoria Palasantzas Received Received
  15-PO4 From alcohol to metabolic dysfunction: a new leading cause of cirrhosis in Mexico Nahum Méndez-Sánchez Received Received
  16-PO5 Prevalence and its associated risk factors of metabolic dysfunction-associated steatotic liver disease among information technology employees in India: A cross-sectional study Bhargava Bharam Received Received
  16-PO2 Circulating CEACAM1 as a biomarker for hepatic steatosis in a metabolic context: Insights from the Portuguese PREVADIAB2 study Rita Patarrão Received Received
  16-PO7 Physics-based modeling of cholesterol and bile acids metabolism: Insights into the enterohepatic circulation and implications for metabolic dysfunction-associated steatotic liver disease (MASLD) Flora Bahrami Received Received
  16-PO3 Gaps in MAFLD screening and management: a retrospective audit of patients at cardiometabolic risk in secondary care Monica Cucco Received Received
  16-PO6 Volatile organic compound metabolites in urine are associated with MASLD and fibrosis: an environmental health study Laurens van Kleef Received Received
  16-PO4 Purified low-fat dietary intervention does not reverse MASLD-associated cerebral hypoxia and neuroinflammation in a MASLD mouse model Matthew Siddle Received Received
  17-PO5 Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease among a general population with metabolic dysfunction Laurens van Kleef Received Received
  17-PO6 Alteration feature of VCAM1 in liver tissue of MASLD condition Yong-Hwi Kang Received Received
  17-PO1 Measuring hepatic steatosis with proton density fat fraction quantification at 0.55T: Pilot study and comparison with 3.0T MRI Rochelle Wong Received Received
  17-PO2 A human stem cell-based hepatic model as a tool for metabolic dysfunction-associated steatotic liver disease modeling and drug screening Raquel Bozzo Received Received
  17-PO7 Missense variations in FADS1 and SCD1 genes oppositely affect lipid profile and cardiovascular risk in Italian children with MASLD: A possible monitoring tool also in adults? Miriam Longo Received Received
  17-PO4 Role of neck circumference as a screening modality in metabolic dysfunction-associated steatotic liver disease in rural area Varathpavee Bhuriveth Received Received
  18-PO1 Mapping the hepatic mtDNA genomic landscape in patients with MASLD: The era of GPT-4 artificial intelligence Miriam Longo Received Received
  18-PO3 Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with inflammatory bowel disease (IBD): A single-center prospective study. Ploutarchos Pastras Received Received
  18-PO6 Integrating multidisciplinary screening for HCV micro-elimination in populations with metabolic disorders: Findings from the LIVE(RO)2 Project in Romania Liana Gheorghe Received Received
  18-PO2 Impact of hepatitis C eradication with direct-acting antivirals on metabolic and liver-related outcomes in diabetic patients: A long-term prospective analysis Clelia Asero Received Received
  18-PO5 NT-proBNP levels ?orrelate with liver fibrosis in MASLD patients Volodymyr Cherniavskyi Received Received
  18-PO7 Prevalence and predictors of steatotic liver disease and significant liver fibrosis in an integrated multidisciplinary healthcare pathway model Angelo Armandi Received Received
  18-PO4 RIPK3 inhibition boosts hepatocyte energy and glucose metabolism while reducing inflammation and fibrosis under metabolic stress Marta Afonso Received Received
  19-PO2 Prevalence of steatotic liver disease in people living with HIV and high prevalence of cardiovascular risk factors Ins Pintassilgo Received Received
  19-PO4 Hepatic miRNA expression in experimental models of metabolic dysfunction-associated steatotic liver disease André L. Simão Received Received
  19-PO6 Alcohol-induced immune-metabolic deregulation exacerbates aortic lesion progression in a novel murine model for MetALD Constanze Hoebinger Received Received
  19-PO3 Bone fragility and fracture risk assessment in metabolic disfunction-associated steatotic liver disease Clelia Asero Received Received
  19-PO7 Cell-specific functions of RIPK3 in hepatocyte-macrophage communication in metabolic-dysfunction associated steatotic liver disease Mariana Isabel Alves Received Received
  19-PO1 Combined mGluR5 inhibition and AMPK activation by MPEP: dual approach to reducing lipid accumulation in hepatic steatosis Michelangelo Trucchi Received Received
  19-PO5 Non-invasive parameters compared to FibroScan for the assessment of liver stiffness and controlled attenuation parameters in patients with fatty liver disease Amal Joseph Received Received
  20-PO1 Liver fibrosis in the elderly: Prevalence and association with cognitive function in the Whitehall II study Chengyi Ding Received Received
  20-PO4 The liver frailty index is a good reflection of muscle function and identifies increased frailty in patients with non-cirrhotic steatotic liver disease compared with healthy controls Guillaume Henin Received Received
  20-PO2 Screening of advanced liver fibrosis and metabolic dysfunction-associated steatotic liver disease assessed by transient elastography in Roma population Robert Nastasa Received Received
  20-PO5 Endoscopic ultrasonography-guided liver biopsy: A good alternative from an endohepatologist point of view María Teresa Alvarez-Nava Received Received
  20-PO3 Liver stiffness measurement by SuperSonic Imagine two-dimensional shear wave elastography to predict hepatocellular carcinoma in non-cirrhotic metabolic dysfunction-associated steatotic liver disease Madalina Gabriela Indre Received Received
  20-PO7 Bile acids as potential metabolic markers to differentiate progression and resolution of metabolic dysfunction-associated steatohepatitis Simon Isfort Received Received
  20-PO6 Baseline liver elastography and its longitudinal changes predict liver related outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Lucrezia Petrucci Received Received
  21-PO6 Communication through gut-derived extracellular vesicles: Implications for liver disease progression Rita Machado de Oliveira Received Received
  21-PO2 Lifestyle modification and cognitive behavioral therapy in the treatment of MASLD Vaclav Smid Received Received
  21-PO5 Serological biomarkers of the extracellular matrix reflecting fibroblast activity and endothelial damage are elevated in patients at risk of MASH with significant liver stiffness Diana Julie Leeming Received Received
  21-PO7 The major importance of a multidisciplinary team to manage patients with a multifactorial disease such as steatotic liver disease Sergio Bronze Received Received
  21-PO1 Minibioreactor arrays (MBRAs) to model microbiome response to tryptophan and alcohol in the context of alcohol-associated liver disease (ALD) ciocan dragos Received Received
  21-PO3 Comparative analysis of prevalence, metabolic profiles, and socio-demographic characteristics of MetALD, MASLD, and ALD in a rural area Varathpavee Bhuriveth Received Received
  22-PO4 Severe metabolic dysfunction-associated steatotic liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota in people with HIV Riccardo Righetti Received Received
  22-PO6 Multi-parametric MRI of the liver and heart are associated with major liver and cardiovascular events: A prospective cohort study Edward Jackson Received Received
  22-PO3 Determinants of liver stiffness improvements and worsening in metabolic dysfunction associated steatotic liver disease: Insights from two cohorts Mirko Zoncapè Received Received
  22-PO7 Non-invasive assessment of liver fat fraction utilizing the electrical properties of tissue Michael Thornton Received Received
  22-PO1 ALD is diagnosed at more advanced stages of fibrosis compared to MetALD and MASLD in the general population Jordi Gratacós-Ginès Received Received
  22-PO2 Natural history of metabolic dysfunction-associated steatotic liver disease: A 5-year community-based follow-up study Julia Uhanova Received Received
  22-PO5 RIPK3 modulates the liver immune microenvironment during MASLD progression towards hepatocellular carcinoma André Cardador Received Received
  23-PO7 Dynamic changes in liver stiffness independently predict liver-related event risk in metabolic dysfunction-associated steatotic liver disease Isabel Veloso Alves Pereira Received Received
  23-PO4 Targeted lipidomics and fatty acids profiles reveal w-oxidation as a rescue pathway of inhibited -oxidation in a rat model of drug-associated microvesicular liver steatosis Margarida Silva Received Received
  23-PO3 Prognostic significance of ELF test compared to liver elastography and liver biopsy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Antonio Liguori Received Received
  23-PO6 Prevalence, reference ranges and determinants of hepatic steatosis and increased liver stiffness in the third trimester of pregnancy using transient elastography Luiza Borges Manna Received Received
  23-PO1 Impact of a multidisciplinary clinic for metabolic dysfunction-associated steatotic liver disease on cardiovascular risk and liver health Mirko Zoncapè Received Received
  23-PO2 Novel point-of-care, rapid breath test to identify subjects with metabolic-dysfunction associated steatotic liver disease with advanced fibrosis - a pilot study Osnat Sella Tavor Received Received
  23-PO5 Prevalence of liver fibrosis in vulnerable individuals from North-Eastern Romania using Transient Elastography Ermina Stratina Received Received
  24-PO6 The impact of COVID - 19 on liver fibrosis progression in mexican patients with metabolic dysfunction associated steatotic liver disease: a case - control study Miriam Gabriela Reyes Zermeño Received Received
  24-PO5 Liver fibrosis in T2DM, prevalence and feasibility of screening with AI in primary care Jude Oben Received Received
  24-PO3 Dynamic change in the enhanced liver fibrosis test to predict adverse outcomes in chronic liver disease YAEL MILGROM Received Received
  24-PO4 Bariatric surgical interventions in steatotic liver disease (SLD): Mapping global research trends of the last two decades (2005-2024) Mobin Ibne Mokbul Received Received
  24-PO7 Enhancing detection of significant fibrosis in people living with HIV: revisiting the conventional ALT cut-off Ahmed Kamel Received Received
  24-PO1 Computational electrophysiology highlights cardiac toxicity risks of Pentoxifylline, a key therapy for fatty liver disease, via sodium current inhibition Chitaranjan Mahapatra Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
07:02
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

SLD Summit 2025

 

23-25 January, Estoril
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 23/01/2025 TO 23/01/2025
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert